Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor

Volotinen M., Mäenpää J., Kautiainen H., Tolonen A., Uusitalo J., Ropo A., Vapaatalo H., Aine E.

2009
European Journal of Pharmaceutical Sciences

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland; Santen Oy, Tampere, Finland; Medcare Oy, Äänekoski, Finland; Novamass Ltd., Oulu, Finland; Santen Oy, Helsinki, Finland; Tampere University Hospital, Department of Eye, Ear and Oral Diseases, Tampere, Finland

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.

Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022